AGP Executive Report
Last update: 12 hours agoGenetics Breakthrough in Iceland: deCODE Genetics in Reykjavík says it has built the first Icelandic pangenome, revealing millions of variants missed by standard genome maps and pinpointing a previously hidden early-onset Parkinson’s risk variant in the GBA1 gene. Eye-Care Deal for Iceland: Lupin’s VISUfarma has signed an exclusive licensing agreement to commercialize YUVEZZI (presbyopia eye drops) across the EU, UK, Switzerland, Norway and Iceland, with deal value up to €75m. Cancer Story, Real Life Impact: A personal account describes a breast cancer diagnosis at 39, then spread to lymph nodes, leading to chemotherapy, surgery and radiotherapy—highlighting how the mental load can hit harder than the physical side. Maternal Health in Focus: An Icelandic woman’s social media account claims the US system left her without reliable primary care access during pregnancy and after a preeclampsia diagnosis, pushing her to return home. Public Health & Safety: Reykjavík’s crematorium permit renewal is still under consideration after the temporary operating permit expired, raising questions about compliance while a replacement is pending. Local Environment Hazard: The Met Office warns of elevated hydrogen sulphide near Múlakvísl during a small glacial outburst flood under Mýrdalsjökull—urging people not to linger near the river source. Work-Life Policy Watch: Zurich is set to pilot a 35-hour working week, aiming for the same pay with fewer hours for shift workers including carers and public services.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[Pharmaceutical Executive Daily: FDA Approves Pasatru]]>](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/24990778-912932933-69ad66ff9a88b963b53a43ee2436f89da07d52ad-1280x720-100x56.jpeg)
